Ninety-five patients undergoing an allogeneic bone marrow transplant (BMT) and developing acute graft-versus-host disease (aGvHD) were randomized to receive low-dose intravenous 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47) or high-dose 6MPred (10 mg/kg/d; n = 48) for 5 days, with subsequent tapering doses. On day 5 patients not responding or progressing on low-dose 6MPred could be switched to high-dose 6MPred. All patients, aged 1 to 55 years, were recipients of unmanipulated BMT from HLA identical sibling donors. Patients were stratified at randomization for age (
Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation / Van Lint, M.T., Uderzo, C., Locasciulli, A., Majolino, I., Scime, R., Locatelli, F., Giorgiani, G., Arcese, W., Iori, A.P., Falda, M., Locatelli, F., Bosi, A., Miniero, R., Alessandrino, P., Dini, G., Rotoli, B., Bacigalupo, A.. - In: BLOOD. - ISSN 0006-4971. - 92:7(1998), pp. 2288-2293.
Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation
Locatelli F.;
1998
Abstract
Ninety-five patients undergoing an allogeneic bone marrow transplant (BMT) and developing acute graft-versus-host disease (aGvHD) were randomized to receive low-dose intravenous 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47) or high-dose 6MPred (10 mg/kg/d; n = 48) for 5 days, with subsequent tapering doses. On day 5 patients not responding or progressing on low-dose 6MPred could be switched to high-dose 6MPred. All patients, aged 1 to 55 years, were recipients of unmanipulated BMT from HLA identical sibling donors. Patients were stratified at randomization for age (I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
